Showing results (111-120 of 127) with videos related to
Sort By:
Pageof 13
European Journal of Pharmacology|May 10, 2016
A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic painBoris Tabakoff, Wenhua Ren, Lauren Vanderlinden, et al.Molecular Cancer Therapeutics|June 6, 2020
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal CancerJoshua M Abbott, Qiong Zhou, Hector Esquer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic studyStephen Leong, Roger B Cohen, Daniel L Gustafson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumorsSamir E Witta, Daniel L Gustafson, A Scott Pierson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumorsMichele Basche, Daniel L Gustafson, Scott N Holden, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.Pageof 13